Jazz Pharmaceuticals (NASDAQ:JAZZ) CEO Renee Gala Sells 1,000 Shares of Company Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Renee Gala sold 1,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $225.37, for a total transaction of $225,370.00. Following the completion of the transaction, the chief executive officer directly owned 140,394 shares in the company, valued at $31,640,595.78. This trade represents a 0.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $227.32 on Friday. The stock has a market capitalization of $14.59 billion, a price-to-earnings ratio of 77.32, a PEG ratio of 0.47 and a beta of 0.38. The company has a fifty day moving average of $229.71 and a 200 day moving average of $217.40. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.58 and a current ratio of 1.82.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the company earned $8.13 EPS. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current fiscal year.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
• Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of JAZZ. Castleark Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $9,214,000. SEB Asset Management AB bought a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $8,765,000. Bank of America Corp DE lifted its stake in Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after acquiring an additional 99,656 shares during the period. California Public Employees Retirement System lifted its stake in Jazz Pharmaceuticals by 10.6% in the first quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company’s stock worth $23,552,000 after acquiring an additional 11,915 shares during the period. Finally, Angeles Wealth Management LLC purchased a new stake in Jazz Pharmaceuticals in the second quarter worth about $1,221,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on JAZZ shares. TD Cowen raised their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Canaccord Genuity Group set a $300.00 target price on Jazz Pharmaceuticals in a research report on Wednesday, August 26th. Truist Financial raised their target price on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Finally, Morgan Stanley boosted their price target on shares of Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $293.45.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.